Rhythm Pharmaceuticals stock edges lower after insider sale but stays backed by strong Q2 growth
Published on 09/02/2026 at 22:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Rhythm Pharmaceuticals stock (ISIN US7733301072) is trading around the 104 dollar mark as of September 2, 2026, implying a market capitalization of about 7.21 billion USD according to recent market data. One market capitalization overview shows the company valued at 7.21 billion USD with a share price reference near 87.39 dollars, underscoring how the stock has appreciated significantly in recent months.
Insider sale puts short-term pressure on the stock
On August 31, 2026, Rhythm Pharmaceuticals chief financial officer Hunter C. Smith sold 62,774 shares of common stock in a planned transaction, with an average price of about 105.46 USD per share and a total value of roughly 6.62 million USD. A trading report notes the average sale price at 105.4563 USD and describes the transaction as part of a broader insider activity pattern. A summary of the Form 4 filing adds that the CFO exercised 57,187 options at 25.79 USD and then sold 62,774 shares in several tranches at weighted average prices around 104.59, 105.37 and 106.20 USD per share under a Rule 10b5-1 plan dated May 13, 2026.
The share sale coincided with a modest price pullback. During trading on September 1, 2026, Rhythm Pharmaceuticals stock traded down by about 1.39 dollars to 104.74 USD, corresponding to a decline of approximately 1.31 percent for the day according to one market commentary. The same commentary reports a trading volume of 322,694 shares, below the average daily volume of 767,008 shares, suggesting that the insider move caused some selling pressure but did not trigger a broad capitulation among investors.
Q2 2026 earnings show strong revenue growth
Despite the short-term price dip, Rhythm Pharmaceuticals fundamentals appear robust based on the most recently reported quarter. In its earnings release for the quarter that ended in the second quarter of 2026, the company generated revenue of about 71.25 million USD, representing year-over-year growth of 46.9 percent compared to the same quarter of the prior year. An earnings overview indicates that the revenue figure of 71.25 million USD exceeded the consensus estimate of about 67.66 million USD, highlighting a positive surprise of 3.59 million USD or roughly 5.3 percent.
On the earnings line, Rhythm Pharmaceuticals reported a per-share loss of 0.73 USD in the same quarter, but this was materially better than the consensus expectation of a loss of 0.81 USD per share. The earnings result therefore beat consensus by 0.08 USD per share, signaling that cost discipline and revenue scaling are beginning to narrow the company’s losses even as it continues to invest in commercial expansion. The same source notes that revenue for the quarter was up 46.9 percent year-over-year and that analysts expect full-year 2026 earnings per share of about negative 2.82 USD, framing a trajectory of gradually improving but still negative profitability.
In a broader peer context, one competitor overview that compares Kailera Therapeutics with Rhythm Pharmaceuticals states that Rhythm currently carries a consensus target price of 141.12 USD, implying a potential upside of about 34.73 percent from a stock level close to 104.74 USD. The competitor comparison simultaneously shows a market capitalization of about 8.11 billion USD for Rhythm Pharmaceuticals, slightly higher than some other market cap snapshots, which underscores the company’s weight-loss treatment footprint in the pharmaceutical sector.
Further facts and filings on Rhythm Pharmaceuticals
Investors who want to follow Rhythm Pharmaceuticals in more detail can find additional figures, filings and news bundled under the company’s ISIN as well as on the official investor relations page.
Market data and investor perspective
Real-time quote data show Rhythm Pharmaceuticals trading at around 104.31 USD as of September 2, 2026, with a recent snapshot reporting net income of negative 0.05 billion USD for the latest quarter and five-year returns that reflect a strong upward trend from earlier lows. A share price overview lists a share price reference of 101.71 USD with a daily gain of 4.61 percent at a prior timestamp, illustrating that the stock has recently moved within a low-100s dollar band and can post sizeable daily swings.
Additional market index data compiled on September 2, 2026, place Rhythm Pharmaceuticals at 104.74 USD with a daily move of negative 1.31 percent, confirming that the stock has eased slightly from recent peaks but remains near triple-digit territory. One index snapshot lists the 104.74 dollar price in the context of broader healthcare and biotechnology moves. For investors, the combination of an insider sale, strong Q2 revenue growth and a consensus target that stands about 36 dollars above the current price encapsulates the central tension between short-term profit taking and longer-term growth expectations.
Imcivree as a flagship obesity treatment
Rhythm Pharmaceuticals is best known for Imcivree, its melanocortin-4 receptor agonist approved for certain rare genetic forms of obesity. The drug targets patients with specific gene deficiencies in the leptin-melanocortin pathway, aiming to reduce excessive hunger and support meaningful weight loss under medical supervision. Recent quarters have seen Imcivree sales drive the bulk of Rhythm’s revenue, with the 71.25 million USD in Q2 2026 revenue reflecting broader adoption in the United States and selected international markets.
The obesity treatment field has become increasingly competitive, with established players in the DACH region such as Novo Nordisk and other European pharmaceutical companies also pursuing metabolic indications. For Rhythm, the key challenge is to expand Imcivree’s labeled indications and reimbursement footprint while preserving pricing power and managing the high cost of specialized treatment. Investors following Rhythm Pharmaceuticals stock therefore pay close attention to updates from regulators, payers and clinical trial results that could extend the drug’s reach or introduce new competitive pressures.
Stock price level and trading venue
Rhythm Pharmaceuticals shares are listed on the Nasdaq exchange under the ticker RYTM, with the latest observed prices around 104 to 105 USD as of September 2, 2026. With a market capitalization in the range of 7.21 to 8.11 billion USD based on different data snapshots, the company sits firmly in the mid-cap segment of the United States biotechnology and pharmaceutical sector. The recent daily decline of about 1.31 percent to 104.74 USD after the CFO’s share sale shows that insider transactions can prompt price reactions, but the scale of the move has remained relatively contained compared to the stock’s broader upward trajectory over the past year.
Key data on Rhythm Pharmaceuticals stock
- Company: Rhythm Pharmaceuticals, Inc.
- ISIN: US7733301072
- Ticker: RYTM
- Trading venue: Nasdaq
- Price (as of September 2, 2026): 104.74 USD
- Market capitalization: 7.21 billion USD (as of September 2, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: Nasdaq biotechnology segment
